// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Assessing awareness in severe Alzheimer's disease

Jonathan D Huntley - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Association between 10-year cardiovascular mortality-risk and neuroimaging biomarkers in the FINGER trial

Gazi Saadmaan Hossain - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Longitudinal trajectories in clinical progression of Alzheimer’s disease tau positron emission tomography subtypes

Boris-Stephan Rauchmann - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Measuring olfactory-related brain region volume loss in MCI and AD using structural MRI

Majed AlOtaibi - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predicting cortical thickness with [18F]flortaucipir PET: a longitudinal MRI study

Denise Visser - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Quantifying AD-related brain amyloid with linearised progression models: model-based vs. data-based.

Alle Meije Wink - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

18F-florbetapir

Rates of cortical thinning in Alzheimer’s disease signature regions: pathological influences and cognitive consequences in members of the 1946 British birth cohort

Sarah E Keuss - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

18F-florbetapir

Subcortical atrophy imaging biomarker performance across the sporadic and genetic frontotemporal dementias

Elizabeth Gordon - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

TDP-43

WMH and biomarker heterogeneity of individuals on the amyloid pathway

Lloyd Prosser - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution

Mahnaz Shekari - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

- First results of the AMYPAD Prognostic and Natural History Study: amyloid-PET Centiloid predicts cognitive functioning in a pre-dementia population

David Vállez García - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

- Two progression patterns in Alzheimer's disease identified from structural MRI in a memory clinic-based cohort

Hannah Baumeister - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

- Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies

Ariane Bollack - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Florbetapir

Transcription-based drug repurposing in Alzheimer disease psychosis

Morteza P Kouhsar - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Alzheimer's disease

N/A

Codesign methods when developing a decision guide for eating and drinking problems among hospital patients with severe dementia

Kanthee Anantapong - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Hippocampal place cells exhibit impairments in spatial information coding in an APP-knock in model of Alzheimer’s Disease

Ruth A Wood - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

- Telomere Length Variation in the Lewy Body Diseases and its Relationship to Epigenetic Age

Jennifer L Imm - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Biomarker evidence of neurodegeneration in chronic kidney disease, in a general population

Anna Dittrich - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology

Pamela C.L. Ferreira - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Consensus harmonization of brain-secreted extracellular vesicles isolation and validation protocols for blood biomarker work in Alzheimer's disease: An international overview

AmanPreet Badhwar - Alzheimer's Association International Conference (AAIC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Copyright © 2026. QuantiNova All rights reserved